Histoacryl Flexible Topical Skin Adhesive April15, 2013



Similar documents
October 28, Cavex Holland Bv Mr. Richard Woortman Manager Technical Services Fustweg 5 Haarlem, 2031CJ The NETHERLANDS

April 7, Acclarent, Inc. Mr. James Patrick Garvey II Sr. Manager, Regulatory Affairs 1525-B O'Brien Drive Menlo Park, CA 94025

Lewis Ward L.W. Ward and Associates, Inc Kirkwood Court Boulder, CO

Q(K SVJM~jPagelIof 3

November 17, Nanova Biomaterials, Inc. Mr. Andrew Ritts Senior Research Scientist 3806 Mojave Ct Columbia, Missouri, 65202

February 22, Life Spine, Incorporated Mr. Randy Lewis General Manager 2401 West Hassell Road, Suite 1535 Hoffman Estates, Illinois 60169

February 5, Dear Kristin Pabst,

GE Healthcare MAR

(k)Suminary k

July 24, Dear Ms. Rhodes:

August 12, Oertli Instrumente AG Ms. Karin Rohr Head of Quality Management & Regulatory Affairs Hafnerwisenstrasse 4 CH 9442 Berneck Switzerland

March 20, Dear Mr. Chen:

May 7, Tactile Systems Technology Inc Daniel Chase V.P. Engineering & Operations 1331 Tyler St NE Minneapolis, Minnesota 55413

Simpler Implant Solutions Inc Arbutus St. Vancouver, BC V6i 3Y9. haroldbergmanl~ogmail.com Telephone Fax K080115

510(k) Summary. Dentsply Implants. April 30, 2013

August 21, TCM Associates Ltd Mr. Iain Alligan Technical Director 3 Hillgrove Business Park Nazeing Road Essex EN9 2HB United Kingdom

January 12, Dear Amy Yang:

Dental Morelli Ltda.

Ni Hau Industrial Co., Ltd. Ms. Lyn Chiu Sales Manager No. 15, Alley 125, Lane 318, Section 2, An Ho Road Tainan City, Taiwan 70967

May 5, Dear Mr. Courtney:

Ad-tech Medical Instrument Corporation. Principal Consultant Quality & Regulatory Associates, LLC. 800 Levanger Lane. Stoughton, Wisconsin 53589

2. Contact Person: Garo Mimaryan, MS., RAC 7 Technical Regulatory Affairs Specialist III 3. Phone Number: (914)

March 3, Dear Ms. Alice Gong,

University of Texas Medical School at Houston. April 14, 2015

May 20, Ivoclar Vivadent Ag Ms. Donna Hartnett Director Regulatory Affairs Ivoclar Vivadent, Inc. 175 Pineview Drive Amherst, New York 14228

510(K) SUMMARY. 510(k) Number KOS'00-r

0 EC V-,) 133 Lj9a

November 20, Vascular Flow Technologies Ltd. Edwin Lindsay VP of QA/RA Prospect Business Centre, Gemini Cresent Dundee DD2 1TY United Kingdom

Phoenix Thera-Lase Systems, LLC Ms. Diane Rutherford Ken Block Consulting 1201 Richardson Drive, Suite 280 Richardson, Texas 75080

June 9, Stryker Corporation Garry T. Hayeck, Ph.D. Senior Regulatory Affairs Specialist 2 Pearl Court Allendale, New Jersey 07401

Section 5-510(k) Summary. This document is provided in the following pages. DEC

October 29, Dear Ms. Hartnett:

SUMMARY OF SAFETY AND EFFECTIVENESS for Powered Muscle Stimulator

510(K) SUMMARY [as required by section (c)] FLIGHT 60 Ventilator 510(k) Number K IaO?2Z, JUL

DICOM Grid, Inc. January 25, Senior Consultant Biologics Consulting Group, Inc. 400 N. Washington Street, Suite 100 ALEXANDRIA VA 22314

EM GR.OUF DIPLOMAT. OT39?1 Company Name: (K)SUMMARY Oc. Submission Correspondent. Emergo Group, Inc. Company Address:

510(k) SUMMARY MANI Needle and Suture Pack MANI, Inc.

kok1 UQ 510(k)J Device {Applicant 510(k) Summary (per 21 CFR (c)) OCT Applicant

Brainreader ApS February 4, 2015 C/O Mette Munch QA Consultant Skagenvej 21 Egaa, 8250 DENMARK

JUN 2 6 butt. EkoSonicTM Endovascular System with Rapid Pulse Modulation

510(k) Summary. Atlanti STM Abutment and AtlantisTM Crown Abutment in Zirconia for Dentsply Ankylos Implant

Ultimate Concepts Inc.

July 21, Dentca, Inc. c/o Mr. Claude Berthoin Denterprise International, Inc. 110 East Granada Blvd, Suite 207 Ormond Beach, Florida 32176

September 25, Dear Ms. McCoy:

SECTION 5 BARDEX TEMPERATURE-SENSING FOLEY CATHETER 510(k) SUMMARY OF SAFETY AND EFFECTIVENESS INFORMATION

Building 6, Suite 300 RyeBrook, NY C-ontact-N~ame: --- William H-. Schofield Director of TeleHealth Operations. Signal,_Radiofrequency

May 22, Rachel s Remedies, LLC Mrs. Rachel E. Jackson 2316 Delaware Ave. #174 Buffalo, New York 14216

JN (k) Summary Device Identification: Device Description:

Koqo8 go. ER35 ERO-SCAN Pro Hearing Test System. 61 Martin Lane Elk Grove Village, IL Manager of Instrumentation Products

D I Z1. 510(k) Summary. Section 5. Siemens Medical Solutions USA, Inc. Oncology Care Systems. Date Prepared: September 09,

BMR ~131o-lvleccai Kesearcn Ltd.

L~l t l V~! MAY ?

Section (K) Summary. Kimberly-Clark Corporation Winchester Road Neenah, WI 54956

MAY Attachment (k) Summary 21 CER

ATLANTIS Anterior Cervical Plate System ATLANTIS Translational Plate. 510(k) Summary. February 2007

510(k) Summary GlobalMedia Group, LIC. MAY CONiM

,11 DSA Cable, transducer and VS3, VS4 electrode, patient connector

March 31, Etiometry, Inc. Richard Galgon Independent Consulting Associate Quintiles 5846 Cobblestone Lane Waunakee, Wisconsin 53597

AW Server 510 (k) Summary of Safety and Effectiveness

Dear Ms. Lucas: This letter corrects our substantially equivalent letter of February 18, 2016.

OCT 18 20U5Ibko. a. Submitter Name: Cosmetic Dental Materials Inc. (CDM Inc.) b. Submitter Address: 812 Water St. NE Albany OR 97321

ItP. Section I. 510(k) Summary of Safety and Effectiveness. Applicant:

foq8 510(k) Summary fo r PAIRIETEX ~ COMPOSITE Mesh

Summary of Safety and Effectiveness

Fresenius Medical Care

51O(K) SUMMARY: Therapy family of devices.

510(k) Summary of Safety and Effectiveness JUN Hip prosthesis

DEC The three components of the Axxent Electronic Brachytherapy System include the Controller, Balloon Applicators-BR and X-ray Source.

AgaMatrucx. NV2 21 Salem, NH oz (k) Sumnmary

KIZ 2,33-3 p8 ~ 510(k) Summary. As required by 21 CFR (c) 510(k) Premarket Notification Submission AFrame Digital MobileCare Monitor.

MViAKIO. V.A hn2 ATTACHMENT I 610(K) SUMMARY. Submitter:

sbchoi~kku.edu jeremy~sooil.com DANA Diabecare IlS Insulin Infusion pump Infusion pump Class II

DEC V,(9/azO (c 0 j

510(k) Summary (c)

RAMSOFT BUG ,-. I"-, --I 2 N Tel: (416) Fax: (416) sales@ramsoftbiz (k) Summary

510(k) SUMMARY APR Date: 15 th December 2008

510(k) SUMMARY JUL Otoharmonics 0 Levo 9 System

MAY SECTION VIII. 510(k) SUMMARY OF SAFETY AND EFFECTIVENESS

ELASTO-GEL MANIJKAH"O"NEY JUUjj 2. fudbthsarltvl of the wound fluid, while re~leas'ing

Datrix, Inc NOV Appendix G. 510(k) Summary of Safety and Effectiveness for Datrix, Inc CardioServer ECG Management System

510(k) SUMMARY. OPTION-vyM Urinary Catheter

Manufacturing Technology, Inc.

510(k) Summary Special Premarket Notification 510(k) Section 6

Food and Drug Administration 5 10(k) Notijfication - Partial & Total Ossicular Replacement Prostheses AUG I June 30, 2006

r5 73~ 9/ / 510(K) Summary (K) SUMMARY

510(K) Summary K102148

I C 5 5l v ri 510(K) SUMMARY. Prowess Panther

MAR (k) SUMMARY OF SAFETY AND EFFECTIVENESS (21CFR ) 1. DATE PREPARED: 4/21/2008

510(k) Summary. (508) X222 Disposable Insulin Delivery Device

March 23, Vision Quest Industries, Inc. Mr. Mohammed Ouerghi Director of QA/RA 1390 Decision Street, Suite A Vista, CA 92081

Transcription:

MAY 17 2013 B. 510(k) SUMMARY (as required by 21 CFR 807.92) Histoacryl Flexible Topical Skin Adhesive April15, 2013 f(i~i9(~pagel1of 3 COMPANY: CONTACT: COMMON NAME:. CLASSIFICATION NAME Aesculapt Inc. 3773 Corporate Parkway Center Valley, PA 18034 Establishment Registration Number: 2916714 Kathy A. Racosky 610-984-92 91 (phone) 610-791-6882 (fax) kathy. mcoskv0-aesculao~com Topical Skin Adhesive Tissue Adhesive REGULATION NUMBER: 878.4010 PRODUCT CODE: MPN DEVICE DESCRIPTION Histoacryl Flexible Topical Skin Adhesive is-a sterile liquid topical skin adhesive composed of n-butyl-2-cyanoacrylate monomer, softener, stabilizer, and colorant (D&C' Violet #2). It-is provided in 0:5 ml single patient use plastic ampoules. Each ampoule is sealed within a foil pouch so the exterior of the ampoule can remain sterile. The tissue adhesives remain, liquid until exposed to water or water-containing substances including tissue, after which it cures (polymerizes) and forms a film that'bonds to the underl ying surface. In vitro studies have shown that Histoacryl Flexible acts as~a barrier to microbial penetration as long as the adhesive film remains intact. Clinical studies were not conducted to demonstrate microbial barrier properties and a correlation between microbial barrier properties and a reduction in infection have not been established. INDICATIONS FOR USE Histoacryl Flexible topical skin adhesive is intended foe topical application to hold closed easily approximated skin edges of minimum-tension -woundstfrnrn clean surgical incisions and simple, thoroughly cleansed, trauma-induced lacerations. Histoacryl Flexible may be used in conjunction with, but not in place of, deep dermal sutures. 81

<'12V(ew ZOC SUBSTANTIAL EQUIVALENCE Aesculap;, Inc: believes thattthe, Histoacryl Ftexible Topical Skin Adhesive is substantially equivalent to the Aesculap Hifstoacryl and I-Iistoacryl Blue Topical Skin Adhesive (K1 1 1959).and Dermabond (P9,600652). PURPOSE FOR PREMARKET NOTIFICATION The purposefor this submission is to gain marketing clearance for the new H-istoacryl Flexible Topical Skin Adhesive. TECHNOLIGICAL CHARACTERkISTICS (compared to Predicateis)) The technological characteristics of tha Aessulap. HistoacrylI Flexible Topical Skin Adhesive are equivalent in performance to the predicate devices Histoacryl and Histoacryl blue Topical Skin Adhesive, Aes -s6lap mind (Kil I 959)-and Dermabond (P960052). The subject device is shown to'be substantially equivalent and has the same performance characteristic to, the predicate devices through comparison in technology,, Indication For UsD,'mechanism of actioni, intended, applicationand performance. Both Histoacryl and Histoacryl Blue Topical Skin Adhesive and H-istoacryl Flexible Topical Skin Adhes'ive devibes use, n-butyl-2-cyanoacrylate to facilitate wound closure. Histoacryl Flexible is designed to bond to the skin to provide flexible wound closure maintaining wound approximation. In vitro studies have shown that Histoacryl acts as a barrier to microbial penetration as long as the adhesive film remains intact. Clinical studies were not conducted to demonstrate microbial barrier properties and'a correlation between microbial barrier properties and a reduction in infection have not been established. The main differences between Histoacryl Flexible and H-istoacryl are " a change in formulation to allow flexible wound closure " storage conditions at orbelow 77 0 F (25 0 OC) V~ersus 72 0 F (22 0 C) Biocompatibility: The biological evaluation of Histoacryl Flexible Topical Skin Adhesive device has been performed in accordance with ISO 10993, "Biological Evaluation of Medical Devices Part -1: Evaluation and Testing, for breached or compromised surfaces with blood contact for the wou~nd closure and subsequent layeradhesives!. Biocompatibility tests were conducted for a 'breached of compromised surface with blood contact device with prolonged contact duration of greater than 24 hours but less than 30 days". Tests include MEM cytotoxicity (ISO 10993-5), intracutaneous reactivity (ISO 10993-10), maximization sensitization (ISO 10993-10), systemic toxicity (ISO 10993-11), and muscle implantation (ISO 10993-6). The results provide evidence that Histoacryl Flexible is safe and biocompatible for its intended use and therefore. substantially equivalent to the predicate devices. 82

Performance testing: 1z21 Page 3of 3 Testing was performed in accordance to FDA's Class 11 SpecialControl Guidance Document for Tissue Adhesive for the Topical Approximation of Skin to demonstrate that the Aesculap Histoacryl Flexible. Topical Skin Adhesive is substantially equivalent to other predicate devices. The following comparative testing demonstrated substantially equivalent performance to Histoacryll and, Histoacrl Blue Topical Skin Adhesive and Dermabond: * Lap shear strength (ASTM F2255-O5) " Peel adhesion strength (ASTM F 2256-05) " Impact strength (ASTM F2458-05), * Set (polymerization) time " Heat of polymerization * Viscosity * GO Chemical. Analysis " Hydrolytic degradation * Ease of expression Microbial barrier testing was conducted using Histoacryl and Histoacryl Flexible. The method was a strike through test that was conducted with common organisms known to cause infections and represent gram positive,, gram negative, motile and non-motile as well as fungi. The challenge was at a minimum concentration of i X 106 cfu. Sterilization and Shelf-Life: Sterilization of Histoacryl Flexible Topical Skin Adhesive is the same as the predicate device, Histoacryl and Histoacryl Blue Topical Skin Adhesive. The sterilization process consists of 1) ETO sterilization of the ampoule, 2) gamma radiation sterilization of the aluminum pouch: both are sterilized before 3 ) the sterility of the liquid topical skin adhesive which is guaranteed by membrane filtration and aseptic'filling. Real-time testing data has been generated to support this submission. Current data supports a 24 month shelf life. Conclusion: Based on the. nonclinical testing Histoacryl.Fleaxible Topical Skin Adhesive has been demonstrated to be substantially equivalent to H-istoacryl and Histoacryl Blue Topical Skin Adhesive and Dermabond. 83

420t.Food * DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service a and Drug Administration 10903 New Hampshire Avenue Document Control Center - W066-G609 Silver Spring MD 20993-002 Aesculap, Inc. Letter dated: May 17, 2013 % Ms. Kathy A. Racosky Senior Regulatory Affairs Specialist 3773 Corporate Parkway Center Valley, Pennsylvania 1 8034 Re: K121976 Trade/Device Name: Aesculap Histoacryl Flexible Topical Skin Adhesive Regulation Number: 21 CFR 878.40 10 Regulation Name: Tissue adhesive Regulatory Class: Class 11 Product Code: MiPN Dated: April 15, 2013 Received: April 18, 2013 Dear Ms. Racosky: We have reviewed your Section 5 10(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRFI does not evaluate information related to contract liability warranties. We remind you; however, that device labeling must be truthful and not misleading. If your device is classified (see above) into either class 11 (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical

Page 2 - Ms. Kathy A. Racosky device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CER Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. If you desire specific advice for your device onour labeling regulation (21 CFR Part 801), please go to http://www.fdajzov/abotitfda/ CentersOffices/CDRH-/C DRI-iOffices/Llcm II 5809.hitm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (2ICFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CER Part 803), please go to littp://www~fda.kuov/medicaldevices/sa fety/reportaproblem/default.htin for the CDRI- H's Office of Surveillance and Biometrics/Division of Postmarket Surveillance. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7 100 or at its Internet address http:h//-ww.fda.izov/medica]devices[resotircesforyou/industry/defaulthtm. Sincerely yours, Mark NFIMjeiLerson -S. Mark N. Melkerson Acting Director Division of Surgical Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure

Page 1 of 1 A. INDICATIONS FOR USE STATEMENT 510(k) Number: K 12zfli4 Device Name: Aesculap H-istoacryl Flexible Topical Skin Adhesive Indications for Use: Histoacryl Flexible topical skin adhesive Is intended for topical application to hold closed easily approximated skin edges of minimum-tension wounds from clean surgical incisions and simple, thoroughly cleansed, trauma-induced lacerations. Histoacryl Flexible may be used in conjunction with, but not in place of, deep dermal sutures. Prescription Use- X and/or Over-the-Counter Use (Part 21 CFR 801 Subpart D) (21 CER 801 Subpart C) (PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) Jiyoupig~ang -S (Division Sign-Off) Division of Surgical Devices 178 510(k)Number: K121976